Diabetes

April 29, 2018

Lighting your way to treat blood sugar disease: Blue light-based therapy for diabetes (TIIDM): Intense blue light increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 29/April/2018, 7.29 am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, […]
April 27, 2018

Blue light-based therapy for TIIDM and obesity-associated metabolic deficits: Intense blue light therapy increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 27/April/2018, 11.32 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
April 24, 2018

Blue light-based therapy for body weight control, energy homeostasis and TIIDM: Blue light therapy decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/April/2018, 11.49 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell […]
April 18, 2018

Treating blood sugar disease with antidepressants: Duloxetine-based therapy for diabetes (TIIDM): Duloxetine (Brand name: Cymbalta), used in the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain and others, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 18/April/2018, 9.49 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]